RxDoctor Payments Data

Timothy Souchek

Physician Assistant · Palo Alto, CANPI 1194709881

Payments from drug & device makers

$13,281in general payments, 2019–2025

Across 707 payments — averaging $18.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Daiichi Sankyo Inc.$912
  • Novartis$895
  • Johnson & Johnson$791
  • Astellas Pharma US Inc$751
  • Pfizer$549
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$13,17999%
  • Education$1021%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)48$1,142
Daiichi Sankyo Inc.56$912
Novartis54$895
Johnson & Johnson48$791
Astellas Pharma US Inc59$751
Pfizer36$549
Exelixis Inc.18$462
Merck22$432
AbbVie24$419
GSK19$387
Amgen16$386
Genentech USA, Inc.20$364
Eisai Inc.19$358
Seagen Inc.18$339
Blueprint Medicines Corporation13$294
E.r. Squibb & Sons, L.L.C.29$286
Pharmaessentia USA Corporation8$280
Takeda Pharmaceuticals U.S.A., Inc.13$280
Sanofi12$279
Bayer14$271
Lilly USA, LLC12$249
Sobi, Inc9$194
Incyte Corporation12$192
Rigel Pharmaceuticals, Inc.7$164
Pharmacyclics LLC, An Abbvie Company6$156
Morphosys, US Inc.8$146
Array Biopharma Inc9$139
Puma Biotechnology, Inc.7$137
AMAG Pharmaceuticals, Inc.6$131
Bristol Myers Squibb6$127
Janssen Scientific Affairs, LLC1$125
Boehringer Ingelheim5$105
AVEO Pharmaceuticals, Inc.5$100
Taiho Oncology, Inc.4$95
Beone Medicines USA, Inc.3$94
Mirati Therapeutics, Inc.5$91
Jazz Pharmaceuticals Inc.4$90
Apellis Pharmaceuticals, Inc.4$84
Ipsen Biopharmaceuticals, Inc4$77
Karyopharm Therapeutics Inc.3$75
ADC Therapeutics America, Inc.2$64
Gilead(2 entities)3$63
Beigene USA, Inc.4$59
Secura Bio, Inc.2$59
Recordati_rare_diseases_inc.3$57
Alnylam Pharmaceuticals Inc.3$57
Stemline Therapeutics Inc.2$54
Genmab U.S., Inc.2$52
Coherus Oncology, Inc.2$42
EMD Serono, Inc.2$41
Deciphera Pharmaceuticals Inc.2$39
Immunogen, Inc.2$32
Pharmacosmos Therapeutics Inc.1$29
Regeneron Healthcare Solutions, Inc.1$28
Tolmar Pharmaceuticals, Inc.2$25
Servier Pharmaceuticals LLC1$22
CTI Biopharma Corp.1$19
Dova Pharmaceuticals1$17
Sun Pharmaceutical Industries Inc.1$17
Cumberland Pharmaceuticals, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,281 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$4,175
Medicare patients
34
Services billed
36

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib46$747,532
BrukinsaZanubrutinib54$552,201
JakafiRuxolitinib Phosphate25$437,189
TasignaNilotinib Hcl21$423,491
RevlimidLenalidomide23$343,477
ErleadaApalutamide20$236,301
XtandiEnzalutamide12$163,002
DopteletAvatrombopag Maleate12$154,947
Lenalidomide11$95,882
PromactaEltrombopag Olamine12$88,462
EliquisApixaban66$55,378
XareltoRivaroxaban27$26,958
ZenpepLipase/Protease/Amylase17$20,501
CreonLipase/Protease/Amylase12$11,477
Fentanyl29$2,894

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$156$747,53246 claims
Beigene USA, Inc.Brukinsa$59$552,20154 claims
NovartisTasigna, Promacta$895$511,95333 claims
Incyte CorporationJakafi$192$437,18925 claims
Bristol Myers SquibbRevlimid$127$343,47723 claims
Johnson & JohnsonErleada, Xarelto$791$263,26047 claims
Astellas Pharma US IncXtandi$751$163,00212 claims
Dova PharmaceuticalsDoptelet$17$154,94712 claims
PfizerEliquis$549$55,37866 claims
AbbVieCreon$419$11,47712 claims
Lilly USA, LLCOlanzapine$249$53340 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Palo Alto

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →